Intracameral Bevacizumab for Iris Rubeosis

Salvatore Grisanti*, Sabine Biester, Swaantje Peters, Olcay Tatar, Focke Ziemssen, Karl Ulrich Bartz-Schmidt

*Corresponding author for this work
168 Citations (Scopus)


Purpose: To determine whether intracameral bevacizumab decreases vascular leakage from iris rubeosis in patients with neovascular glaucoma. Design: Interventional case series. Methods: The study included six eyes of three patients with secondary neovascular glaucoma due to proliferative diabetic retinopathy (n = 2) or ischemic central retinal vein occlusion (n = 1). All patients received an intracameral injection of 1.0 mg bevacizumab. Morphologic changes and vascular leakage were investigated prospectively by iris fluorescein angiography. Results: Decrease in leakage was detected as early as one day after injection. No inflammation was observed. No relapse was seen within the follow-up of four weeks. Conclusion: Intraocular injection of bevacizumab may provide an additional strategy for the treatment of iris rubeosis in neovascular glaucoma.

Original languageEnglish
JournalAmerican Journal of Ophthalmology
Issue number1
Pages (from-to)158-160
Number of pages3
Publication statusPublished - 01.07.2006


Dive into the research topics of 'Intracameral Bevacizumab for Iris Rubeosis'. Together they form a unique fingerprint.

Cite this